A pharmaceutical composition in unit dosage form for the treatment of diabetes mellitus and conditions associated with diabetes mellitus, comprising 1 to 12 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (compound I) in the form of a maleate salt or a pharmaceutically acceptable solvate thereof, a sulphonylurea selected from glibenclamide, glipizide, gliclazide, glimepiride, tolazamide, tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliqui...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of 2-12 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione Compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable derivative thereof and a sub-maximal amount of a sulphonylurea(insulin secretagogue), to a mammal in need thereof...

1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, with positive effect by glycemic control without observable unfavourable effects, which method comprises administering 2 to 12 mg daily 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound I) or a pharmaceutically acceptable salt thereof , and sulfonyl urea. 2. A method according to Claim 1, wherein the c is glibenclamide, glipizide, gliclazide, glimepir...